Sign In
Buy CNS
$80.79
-1.71 (-2.07%)
At Close: Jul 21, 2026
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal
Cohen & Steers, Inc. to Release Third Quarter 2025 Results on October 16, 2025
04:42pm, Wednesday, 08'th Oct 2025
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release third quarter 2025 results after the market closes on Thursday, October 16, 2025. The earn
Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for September 2025
04:28pm, Wednesday, 08'th Oct 2025
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $90.9 billion as of September 30, 2025, an increase of $542 million from
AB vs. CNS: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 08'th Oct 2025
Investors looking for stocks in the Financial - Investment Management sector might want to consider either AllianceBernstein (AB) or Cohen & Steers Inc (CNS). But which of these two companies is the b
Integra LifeSciences to Spotlight Neurosurgical Product Portfolio at the Congress of Neurological Surgeons (CNS) Annual Meeting
08:30am, Wednesday, 08'th Oct 2025
Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post Featuring Durepair® Dura Regeneration Matrix and Mayfield® Ghost™ Base Unit, Post
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigatio
Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
05:52pm, Monday, 29'th Sep 2025
NEW YORK , Sept. 29, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources
Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
05:51pm, Monday, 29'th Sep 2025
NEW YORK , Sept. 29, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Total Return Realty Fund, Inc. (NYSE: RFI) (the "Fund") with information regarding the sources of t
Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
05:39pm, Monday, 29'th Sep 2025
NEW YORK , Sept. 29, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers REIT and Preferred and Income Fund, Inc. (NYSE: RNP) (the "Fund") with information regarding the so
Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
05:35pm, Monday, 29'th Sep 2025
NEW YORK , Sept. 29, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") with information regarding the sources of
Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
05:28pm, Monday, 29'th Sep 2025
NEW YORK , Sept. 29, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the di
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it h
Corero Network Security Enters Singapore Market Through Partnership with ONESECURE Asia
07:00am, Thursday, 25'th Sep 2025
LONDON , Sept. 25, 2025 /PRNewswire/ -- Today, Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, annou
MapLight Therapeutics Starts $100 Million IPO Effort For CNS Treatments
02:14pm, Wednesday, 24'th Sep 2025
MapLight Therapeutics is a clinical-stage biopharma focused on CNS disorders and has filed for a $100 million U.S. IPO to fund its pipeline. MPLT's lead drug, ML-07C-MA, targets schizophrenia and Alzh
Corero Network Security Expands Partnership with Netceed to Strengthen UK Network Resilience
07:00am, Wednesday, 24'th Sep 2025
New agreement brings advanced DDoS protection, traffic analysis, and Zero Trust controls to UK service providers LONDON , Sept. 24, 2025 /PRNewswire/ -- Today, Corero Network Security (AIM: CNS) (OTCQ
